BRAF and neoplasm: In recent years, advances in molecular tumor research identified abnormalities in the mitogen-activated protein kinase/extracellular-signal- regulated kinase (MAPK/ERK) activation pathway, due to a mutation or fusion of the BRAF gene, that were present in pLGG but not in aLGG [74,75,76].